ASCO 2025
Advertisement
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Long-term results support the durable efficacy of binimetinib plus imatinib in treatment-naïve advanced GIST.
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Dr. Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ BTC.
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
A post hoc analysis of the NAPOLI 3 trial offers insight into prolonged survival in mPDAC.
A therapy has shown a statistically significant OS benefit in patients with unresectable locally advanced pancreatic cancer.
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.